{"id":"W4286293830","doi":"10.1200/jco.2022.40.16_suppl.tps1118","title":"KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Metastatic breast cancer; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Placebo; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005644348,0.0003776161,0.006356704,0.0004264677,0.0000928133,0.00001172094,0.0004019354,0.0001356243,0.001388284],"category_scores_gemma":[0.0006768527,0.0002232796,0.0005789105,0.0005882421,0.0003476226,0.0001990216,0.00009964834,0.001825773,0.00000162189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001131408,"about_ca_system_score_gemma":0.005184896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000225996,"about_ca_topic_score_gemma":0.0003878339,"domain_scores_codex":[0.9910008,0.00221894,0.004662701,0.0004193926,0.001246064,0.0004521043],"domain_scores_gemma":[0.9910551,0.002855134,0.004387053,0.0003657563,0.000969257,0.0003676968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.862376,0.03032695,0.006744324,0.000054119,0.003276696,0.0003633017,0.001283148,0.004446819,0.000006533595,0.000007578245,0.00007588446,0.09103866],"study_design_scores_gemma":[0.9208191,0.06873747,0.004758952,0.0001884925,0.001499791,0.0002815307,0.001565857,0.0006382221,0.000005892793,0.00003778321,0.001260093,0.0002068122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900392,0.0006867844,0.0003309371,0.002786736,0.0008484522,0.005160654,0.0000287959,0.00001293462,0.0001054963],"genre_scores_gemma":[0.9962495,0.0002946383,0.0009323916,0.001352076,0.0003038641,0.0005998916,0.000006092916,0.00006085504,0.0002007157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09083185,"threshold_uncertainty_score":0.9995246,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07995130304151785,"score_gpt":0.4552754857975471,"score_spread":0.3753241827560293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}